Literature DB >> 8787880

Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.

D P Nicolau1, C H Nightingale, M A Banevicius, Q Fu, R Quintiliani.   

Abstract

Since beta-lactam antibiotics have concentration-independent killing, bacterial eradication is a function of the time the serum drug concentration remains above the drug's MIC (T > MIC). We compared the serum bactericidal titers (SBTs) of ceftazidime given by continuous infusion (CI) or by intermittent bolus dosing (BD) against two clinical isolates each of Pseudomonas aeruginosa and Escherichia coli to determine if CI would allow lower daily dosing while still providing equal bactericidal activity compared with BD. This was an open-labeled, randomized, steady-state, four-way crossover study with 12 healthy volunteers. The ceftazidime regimens were 1 g every 8 h (q8h) BD, 1 g q12h BD, 3 g over 24 h CI, and 2 g over 24 h CI. The areas under the bactericidal curves were calculated by the trapezoidal rule using the reciprocal of the SBT. For all organisms the areas under the bactericidal curves for intermittent versus the CI regimens were the same for equal doses (P > 0.05). For both strains of E. coli all four regimens provided SBTs of > or = 1:2 over the dosing interval and 100% T > MIC. The 1-g q8h BD and q12h BD regimens provided T > MIC of 82 and 52%, respectively, for both P. aeruginosa isolates (MICs, 4 micrograms/ml). In comparison, the 2- and 3-g CI regimens always maintained SBTs of > or = 1:2 and T > MIC over the 24-h period as serum drug concentrations were 12.8 +/- 3.0 and 18.2 +/- 4.5 micrograms/ml, respectively. CI optimizes the pharmacodynamic and pharmacoeconomic profile of ceftazidime by providing adequate antibacterial activity over the 24-h dosing period with a reduction in the total daily dose of the antimicrobial agent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8787880      PMCID: PMC163057     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design.

Authors:  S C Ebert; W A Craig
Journal:  Infect Control Hosp Epidemiol       Date:  1990-06       Impact factor: 3.254

2.  Choosing between the new cephalosporin antibiotics: a pharmacodynamic approach.

Authors:  D P Nicolau; R Quintiliani
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

3.  Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve.

Authors:  S L Barriere; E Ely; J E Kapusnik; J G Gambertoglio
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

4.  Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; J C van den Berg; M F Michel
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

5.  Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model.

Authors:  J J Mordenti; R Quintiliani; C H Nightingale
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

6.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

7.  Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests.

Authors:  L B Reller; C W Stratton
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

8.  Effects of method of antibiotic administration on extravascular penetration: cross-over study of cefazolin given by intermittent injection or constant infusion.

Authors:  L R Peterson; D N Gerding; C E Fasching
Journal:  J Antimicrob Chemother       Date:  1981-01       Impact factor: 5.790

9.  Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.

Authors:  J W Mouton; A M Horrevorts; P G Mulder; E P Prens; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

10.  Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.

Authors:  D Kalman; S L Barriere; B L Johnson
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

View more
  27 in total

1.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

Review 2.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

3.  Community-based parenteral anti-infective therapy (CoPAT). Pharmacokinetic and monitoring issues.

Authors:  D N Williams; J L Raymond
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

Review 4.  Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters.

Authors:  Sofia K Kasiakou; Kenneth R Lawrence; Nicolaos Choulis; Matthew E Falagas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  M Manduru; L B Mihm; R L White; L V Friedrich; P A Flume; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 6.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

Review 7.  Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.

Authors:  Joseph L Kuti; Blair Capitano; David P Nicolau
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

8.  Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy.

Authors:  Julia Langgartner; Antje Vasold; Thomas Glück; Michel Reng; Frieder Kees
Journal:  Intensive Care Med       Date:  2008-02-23       Impact factor: 17.440

9.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 10.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.